Andrei L. Lukyanov

Andrei L. Lukyanov

Auto-generated profile, based on publicly available information

Andrei L. Lukyanov

City Clinical Hospital No. 31 named after Academician G.M. Savelyeva, Moscow, Russia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2025 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
NSN. A. Shamalov
N. A. Shamalov
DKD. R. Khasanova
D. R. Khasanova
SMS. V. Marchenko
S. V. Marchenko
MSM. A. Soldatov
M. A. Soldatov
TAT. P Alekseeva
T. P Alekseeva
NMN. A. Marskaya
N. A. Marskaya
Thrombolytic therapy (TLT) of ischemic stroke (IS) with alteplase within the first 4.5 hours from the onset of symptoms is the most effective and proven method of treatment.Objective: to evaluate the safety and efficacy of TLT with Revelisa (alteplase) in IS in real-world clinical practice.Material and methods. The results of TLT with Revelisa were analyzed in 1181 patients with IS: 616 (52.2%) women and 565 (47.8%) men (mean age 68.28±12.56 years), of which 140 (11.9%) with staged reperfusion. The mean time from disease onset to TLT was 2.58±0.83 hours. The Heidelberg classification was used to assess hemorrhages during neuroimaging. Symptomatic hemorrhagic transformation (HT) was defined according to ECASS III criteria. The study group was characterized by high comorbidity: arterial hypertension (96.9%), ischemic heart disease (56.7%), chronic heart failure (55.8%) and cardiac arrhythmias (33.3%) were most common; diabetes mellitus was present in 23% of patients. IS occurred repeatedly in 15.4% of cases.Results. An improvement of 4 points or more on the NIHSS scale one day after TLT was observed in 41% of patients. The dynamics of the decrease in neurological symptoms one day later and at the time of discharge were statistically significant (p<0.001). The hospital mortality rate for the entire group was 8%, for the TLT group without endovascular intervention 5.6%. Twenty-nine patients (2.46%) had symptomatic HT, 14 of whom underwent endovascular intervention. The proportion of patients with a favorable clinical outcome (0–2 points on the modified Rankin scale) at discharge and at day 90 was 50.1% and 65.5%, respectively.Conclusion. The results of the PRIMA study confirm the high level of efficacy and safety of Revelisa in patients with IS, including during staged reperfusion. The data obtained are consistent with the published registry studies on alteplase in IS.

28 December 2025 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
NSN A Shamalov
N A Shamalov
DKD R Khasanova
D R Khasanova
SMS V Marchenko
S V Marchenko
MSM A Soldatov
M A Soldatov
AAA G Azarova
A G Azarova
NMN A Marskaya
N A Marskaya
Objective. The study aimed to evaluate the efficacy and safety of Revelise (alteplase), a Russian medicinal product used as thrombolytic therapy (TLT) to treat ischemic stroke (IS) in real-world practice. Material and methods. A total of 2202 patients with IS were included in the study. The mean age was 68 years, with 20% of patients aged 80 years or older. Of the patients, 53.6% were men and 46.4% were women; 233 (10.6%) patients with large vessel occlusion underwent staged reperfusion. The most common comorbidities were hypertension (96%), chronic heart failure (57.3%), coronary artery disease (56.9%), and cardiac arrhythmias (33.8%). Nearly one-third (28.9%) of patients received antiplatelet agents before TLT, whereas 4.7% received anticoagulants. The mean NIHSS score for the entire study population was 10, and 11.6% had disabling symptoms with a NIHSS score< 5. Symptomatic hemorrhagic transformation was determined using the ECASS 3 criteria. Results. A substantial reduction in neurological deficit was reported within one day, which differed significantly from the previous value (p< 0.001). Twenty-four hours after TLT, 42.8% of patients demonstrated a decrease in their NIHSS score by ≥4. The hospital mortality rate was 8.2%. Symptomatic hemorrhagic transformation developed in 2.5% of patients. Favorable outcomes (mRS 0—2) were reported in 49.9% of patients at discharge and 66.4% of patients 90 days after TLT. Conclusion. The obtained results confirm the high efficacy and safety of Revelise in patients with IS. The wide practical use in various patient groups is justified by an up-to-date patient selection algorithm. This includes patients aged 80 years and older with minor stroke (NIHSS score< 5) who receive treatment with antiplatelet agents or anticoagulants, as well as staged reperfusion. The obtained results are consistent with those of previously published studies with a similar design.

29 July 2025 in The Russian Archives of Internal Medicine
Verified
Journal Article
Open access
PDF file
ERElena Reznik
Elena Reznik
PMP. A. Mogutova
P. A. Mogutova
MSM. Kh. Shurdumova
M. Kh. Shurdumova
EAE. V. Astashkevich
E. V. Astashkevich
ALA. L. Lukyanov
A. L. Lukyanov
GGG. N. Golukhov
G. N. Golukhov
Guillain-Barré Syndrome is a severe autoimmune disease of the peripheral nervous system, representing the most common cause of acute flaccid tetraparesis, which can lead to life-threatening respiratory failure in the absence of adequate therapy. The relationship between GBS and infective endocarditis is not well studied.A 54-year-old patient experienced increasing numbness and weakness in the lower extremities two weeks after an acute respiratory viral infection, and was hospitalized with suspected ischemic stroke. Brain computed tomography revealed no data for acute focal pathology but showed left-sided sinusitis and ethmoiditis. Cerebrospinal fluid analysis showed protein at 0.8 g/L (normal up to 0.2 g/L), with cytosis within normal limits. The neostigmine test was negative. The clinical and instrumental picture was assessed as Guillain-Barré Syndrome. Echocardiography revealed vegetations on the mitral valve (MV) leaflets, rupture of the anterior leaflet chordae (“flail leaflet” of the MV), and grade 3 mitral regurgitation. Despite ongoing therapy, including antibacterial and immunomodulatory treatment, the patient continued to exhibit neurological symptoms, developed pulmonary artery thromboembolism, nosocomial bilateral polysegmental pneumonia, and sepsis, leading to a fatal outcome. Autopsy confirmed infective endocarditis with rupture of the MV chordae, abundant growth of Pseudomonas aeruginosa, scant growth of Klebsiella pneumoniae and Acinetobacter baumannii, and right atrial thrombosis. No pathological changes were found in the brain substance.Thus, Guillain-Barré Syndrome in rare cases can be associated with infective endocarditis and negatively impact the course and prognosis of the disease.

6 April 2026 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
KIK.A. Ismailova
K.A. Ismailova
LLL.R. Laipanova
L.R. Laipanova
AKA.P. Krasnikov
A.P. Krasnikov
ALA.L. Lukyanov
A.L. Lukyanov
AZA.G. Zlatovratsky
A.G. Zlatovratsky
LKL.T. Khasanova
L.T. Khasanova
The article presents a clinical case of hybrid treatment for tandem occlusion of the internal carotid artery (ICA) and the middle cerebral artery (MCA). The procedure was performed by a single surgical team in one operating room. First, an eversion carotid endarterectomy (ECEAE) for ICA was performed, followed by a common carotid artery (CCA) puncture and aspiration thrombectomy from MCA. The time from symptom onset to revascularization was 180 min. The outcome is favorable; the patient was discharged from the hospital with a neurological deficit of 2 points according to the National Institutes of Health Stroke Scale, 1 point on the modified Rankin Scale, and 13 points on the Rivermead Mobility Index. The paper presents a review of the literature on outcomes of surgical treatment for tandem occlusions in the ICA system.

29 June 2026 in Complex Issues of Cardiovascular Diseases
Verified
Journal Article
Open access
PDF file
NGNikita I. Grachev
Nikita I. Grachev
YKYevgeny I. Kretov
Yevgeny I. Kretov
MLMark A/ Loskutnikov
Mark A/ Loskutnikov
ALAndrei L. Lukyanov
Andrei L. Lukyanov
DSDmitry Yu. Saiko
Dmitry Yu. Saiko
APAndrey V. Popov
Andrey V. Popov
Highlights For the first time in real-world clinical practice across several Russian regions, the high reproducibility and efficacy of the domestic Grasper stent-retriever for mechanical thrombectomy in stroke patients have been demonstrated. An unique routing ecosystem “UDAR” was developed, integrating the pre-hospital stage, “Tele-PVU” telemedicine support, and automated 5–7-minute express CT scan evaluation driven by artificial intelligence. The synergy of digital control and domestic medical devices enabled a 2.5-fold increase in mechanical thrombectomy volumes and reduced hospital mortality from ischemic stroke by 8.1%.   Aim . Analyze the results of the pilot project “UDAR” (Smile, Movement, Articulation, Solution) on reorganizing the routing of patients with acute cerebral blood circulation disorders (AHC) when using telemedicine in the territory of Primordia, to assess the effectiveness of modern methods of reperfusion using domestic stencil-reducers. Methods . The total number of patients suspected stroke included in the study was 18500. All patients at the pre-hospital stage were examined by a paramedic/ doctor of the emergency medical team, who entered on the tablet into the program “UDAR” patient data, then information was sent to the questionnaire of the program “UDAR” with automatic notification of the control center on the basis of a regional vascular center (RVC). The on-duty neurologist of the RVC then analyzed the data and gave recommendations for further routing to the primary vascular unit (PVU) or RVC (with LAMS > 3 points). If necessary, the neurologist of the RVC could conduct a telemedicine consultation with the medical doctor of the emergency medical team by video call to clarify the neurological status of the patient. Upon arrival of the patient in the PVU and CT-study of the brain, data was loaded into “UDAR” program. Control center radiologist had access to the patient’s CT scans. The first series of images was processed by artificial intelligence (AI) with identification of areas of detected pathologies, determination of the extent of lesions, scoring according to the ASPECTS scale prepared by an X-ray report. The second series was a native CT image. Based on the results of the examinations, the neurologist decided to leave the patient in the PVU or transfer to the RVC for mechanical thrombosis extraction. Results . During the lifetime of the project, there was an increase in the frequency of thrombolytic therapy (TLT) from 3.9% to 8.6% (by 4.6%), the number of mechanical thrombosis extractions increased by 1.5 times in 2022 compared to 2021 and 2.5 times in 2023 compared to 2021. Hospital mortality rates from ischaemic stroke in the Primorsky PVU have decreased from 21.7% in 2021 to 14.9% in 2022 and 13.6% in 2023. Conclusion . According to the data obtained from the pilot project, it was found that it is advisable to scale its results to other regions of the country.